GemPharmatech Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
1,590
- Stock Symbol
-
688046
- Investments
-
2
- Share Price
-
$4.03
- (As of Friday Closing)
GemPharmatech General Information
Description
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
Contact Information
Website
www.gempharmatech.comCorporate Office
- No. 12, Xuefu Road
- Jiangbei New District, Jiangsu Province
- Nanjing, 210032
- China
Corporate Office
- No. 12, Xuefu Road
- Jiangbei New District, Jiangsu Province
- Nanjing, 210032
- China
GemPharmatech Stock Performance
As of 20-Nov-2026, GemPharmatech’s stock price is $4.03. Its current market cap is $1.65B with 410M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.03 | $4.35 | $1.87 - $6.45 | $1.65B | 410M | 9.9M | $0.07 |
GemPharmatech Financials Summary
As of 30-Sep-2026, GemPharmatech has a trailing 12-month revenue of $137M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,201,494 | 775,581 | 592,361 | 1,012,069 |
| Revenue | 136,638 | 110,326 | 95,720 | 87,943 |
| EBITDA | 32,987 | 34,577 | 27,033 | 28,361 |
| Net Income | 29,430 | 19,835 | 15,305 | 22,462 |
| Total Assets | 433,480 | 409,488 | 352,412 | 363,625 |
| Total Debt | 31,119 | 41,636 | 18,148 | 17,158 |
GemPharmatech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GemPharmatech Comparisons
Industry
Financing
Details
GemPharmatech Competitors (2)
One of GemPharmatech’s 2 competitors is Cyagen, a Venture Capital-Backed company based in Santa Clara, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cyagen | Venture Capital-Backed | Santa Clara, CA | ||||
| Taconic Biosciences | Private Equity-Backed | Rensselaer, NY |
GemPharmatech Patents
GemPharmatech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026061268-A1 | Three-mutation alzheimer's disease mouse model, construction method, and use thereof | Pending | 20-Sep-2024 | ||
| AU-2025206075-A1 | Animal model and construction method therefor | Pending | 02-Jan-2024 | ||
| EP-4835087-A1 | Animal model and construction method therefor | Pending | 02-Jan-2024 | ||
| WO-2025146085-A1 | Animal model and construction method therefor | Inactive | 02-Jan-2024 | ||
| AU-2025205864-A1 | Animal model for producing humanized antibody and construction method therefor | Pending | 02-Jan-2024 | A01K67/0278 |
GemPharmatech Signals
GemPharmatech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
GemPharmatech Investments & Acquisitions (2)
GemPharmatech’s most recent deal was a Merger/Acquisition with Baimai Biotechnology for . The deal was made on 16-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Baimai Biotechnology | 16-Nov-2026 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Pet Medtech | 15-Dec-2024 | Early Stage VC | Drug Discovery |
GemPharmatech ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
GemPharmatech FAQs
-
When was GemPharmatech founded?
GemPharmatech was founded in 2017.
-
Where is GemPharmatech headquartered?
GemPharmatech is headquartered in Nanjing, China.
-
What is the size of GemPharmatech?
GemPharmatech has 1,590 total employees.
-
What industry is GemPharmatech in?
GemPharmatech’s primary industry is Discovery Tools (Healthcare).
-
Is GemPharmatech a private or public company?
GemPharmatech is a Public company.
-
What is GemPharmatech’s stock symbol?
The ticker symbol for GemPharmatech is 688046.
-
What is the current stock price of GemPharmatech?
As of 20-Nov-2026 the stock price of GemPharmatech is $4.03.
-
What is the current market cap of GemPharmatech?
The current market capitalization of GemPharmatech is $1.65B.
-
What is GemPharmatech’s current revenue?
The trailing twelve month revenue for GemPharmatech is $137M.
-
Who are GemPharmatech’s competitors?
Cyagen and Taconic Biosciences are competitors of GemPharmatech.
-
What is GemPharmatech’s annual earnings per share (EPS)?
GemPharmatech’s EPS for 12 months was $0.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process